UA80399C2 - Use of specific dose of fondaparinux sodium for the treatment of acs - Google Patents
Use of specific dose of fondaparinux sodium for the treatment of acs Download PDFInfo
- Publication number
- UA80399C2 UA80399C2 UA2004032373A UA2004032373A UA80399C2 UA 80399 C2 UA80399 C2 UA 80399C2 UA 2004032373 A UA2004032373 A UA 2004032373A UA 2004032373 A UA2004032373 A UA 2004032373A UA 80399 C2 UA80399 C2 UA 80399C2
- Authority
- UA
- Ukraine
- Prior art keywords
- sulfo
- sulfoamino
- deoxy
- glucopyranosyl
- treatment
- Prior art date
Links
- XEKSTYNIJLDDAZ-JASSWCPGSA-F fondaparinux sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C(O)=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-F 0.000 title claims description 22
- 229960003661 fondaparinux sodium Drugs 0.000 title description 17
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 6
- 229940116269 uric acid Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 description 15
- 208000034158 bleeding Diseases 0.000 description 15
- 231100000319 bleeding Toxicity 0.000 description 15
- 230000000740 bleeding effect Effects 0.000 description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 229960000610 enoxaparin Drugs 0.000 description 12
- 206010000891 acute myocardial infarction Diseases 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 206010002388 Angina unstable Diseases 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 208000007814 Unstable Angina Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010056457 Intra-abdominal haematoma Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204323 | 2001-11-13 | ||
| PCT/EP2002/012482 WO2003041722A1 (en) | 2001-11-13 | 2002-11-07 | Use of specific dose of fondaparinux sodium for the treatment of acs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80399C2 true UA80399C2 (en) | 2007-09-25 |
Family
ID=8181220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2004032373A UA80399C2 (en) | 2001-11-13 | 2002-07-11 | Use of specific dose of fondaparinux sodium for the treatment of acs |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US20040248848A1 (xx) |
| EP (1) | EP1446131B1 (xx) |
| JP (1) | JP4523276B2 (xx) |
| KR (1) | KR20050044318A (xx) |
| CN (1) | CN1602197A (xx) |
| AP (1) | AP1820A (xx) |
| AR (1) | AR037291A1 (xx) |
| AT (1) | ATE361753T1 (xx) |
| AU (1) | AU2002351915B2 (xx) |
| BR (1) | BR0212915A (xx) |
| CA (1) | CA2465776A1 (xx) |
| CO (1) | CO5580790A2 (xx) |
| CY (1) | CY1106765T1 (xx) |
| DE (1) | DE60220084T2 (xx) |
| DK (1) | DK1446131T3 (xx) |
| EA (1) | EA007325B1 (xx) |
| EC (1) | ECSP045041A (xx) |
| ES (1) | ES2287343T3 (xx) |
| GE (1) | GEP20074097B (xx) |
| HK (1) | HK1070561A1 (xx) |
| HR (1) | HRP20040303B1 (xx) |
| HU (1) | HU228959B1 (xx) |
| IL (2) | IL161114A0 (xx) |
| IS (1) | IS2484B (xx) |
| MA (1) | MA27071A1 (xx) |
| ME (2) | ME00229B (xx) |
| MX (1) | MXPA04003045A (xx) |
| NO (1) | NO20041320L (xx) |
| NZ (1) | NZ552129A (xx) |
| PE (1) | PE20030740A1 (xx) |
| PL (1) | PL206008B1 (xx) |
| PT (1) | PT1446131E (xx) |
| RS (1) | RS50906B (xx) |
| SI (1) | SI1446131T1 (xx) |
| UA (1) | UA80399C2 (xx) |
| WO (1) | WO2003041722A1 (xx) |
| ZA (1) | ZA200402464B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075910A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fondaparinux |
| BR112017020091A2 (pt) * | 2015-03-20 | 2018-11-06 | Aarhus Universitet | inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas |
| US10688249B2 (en) * | 2015-06-11 | 2020-06-23 | Virchow Biotech Pvt. Ltd. | Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same |
| CN107595769A (zh) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | 一种磺达肝癸钠注射液组合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662442A1 (fr) * | 1990-05-23 | 1991-11-29 | Midy Spa | Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant. |
| CA2199642C (en) * | 1997-03-10 | 2001-05-08 | Roger Cariou | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
| FR2764511B1 (fr) * | 1997-06-13 | 2000-09-08 | Sanofi Sa | Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire |
| US20040087543A1 (en) * | 2002-04-25 | 2004-05-06 | Zachary Shriver | Methods and products for mucosal delivery |
-
2002
- 2002-07-11 UA UA2004032373A patent/UA80399C2/uk unknown
- 2002-11-07 ES ES02787601T patent/ES2287343T3/es not_active Expired - Lifetime
- 2002-11-07 WO PCT/EP2002/012482 patent/WO2003041722A1/en active IP Right Grant
- 2002-11-07 DE DE60220084T patent/DE60220084T2/de not_active Expired - Lifetime
- 2002-11-07 DK DK02787601T patent/DK1446131T3/da active
- 2002-11-07 AT AT02787601T patent/ATE361753T1/de active
- 2002-11-07 CA CA002465776A patent/CA2465776A1/en not_active Abandoned
- 2002-11-07 EP EP02787601A patent/EP1446131B1/en not_active Expired - Lifetime
- 2002-11-07 PE PE2002001086A patent/PE20030740A1/es not_active Application Discontinuation
- 2002-11-07 SI SI200230578T patent/SI1446131T1/sl unknown
- 2002-11-07 AP APAP/P/2004/003014A patent/AP1820A/en active
- 2002-11-07 MX MXPA04003045A patent/MXPA04003045A/es active IP Right Grant
- 2002-11-07 IL IL16111402A patent/IL161114A0/xx unknown
- 2002-11-07 PL PL369027A patent/PL206008B1/pl unknown
- 2002-11-07 PT PT02787601T patent/PT1446131E/pt unknown
- 2002-11-07 HU HU0401462A patent/HU228959B1/hu unknown
- 2002-11-07 JP JP2003543609A patent/JP4523276B2/ja not_active Expired - Fee Related
- 2002-11-07 US US10/492,102 patent/US20040248848A1/en not_active Abandoned
- 2002-11-07 CN CNA028192567A patent/CN1602197A/zh active Pending
- 2002-11-07 RS YUP-267/04A patent/RS50906B/sr unknown
- 2002-11-07 BR BR0212915-9A patent/BR0212915A/pt not_active Application Discontinuation
- 2002-11-07 ME MEP-2008-11A patent/ME00229B/me unknown
- 2002-11-07 AU AU2002351915A patent/AU2002351915B2/en not_active Expired
- 2002-11-07 NZ NZ552129A patent/NZ552129A/en not_active IP Right Cessation
- 2002-11-07 GE GE5516A patent/GEP20074097B/en unknown
- 2002-11-07 KR KR1020047004779A patent/KR20050044318A/ko not_active Application Discontinuation
- 2002-11-07 EA EA200400382A patent/EA007325B1/ru unknown
- 2002-11-07 ME MEP-11/08A patent/MEP1108A/xx unknown
- 2002-11-11 AR ARP020104308A patent/AR037291A1/es unknown
-
2004
- 2004-03-25 IL IL161114A patent/IL161114A/en active IP Right Grant
- 2004-03-29 ZA ZA2004/02464A patent/ZA200402464B/en unknown
- 2004-03-29 IS IS7199A patent/IS2484B/is unknown
- 2004-03-30 NO NO20041320A patent/NO20041320L/no not_active Application Discontinuation
- 2004-03-30 HR HR20040303A patent/HRP20040303B1/xx not_active IP Right Cessation
- 2004-03-31 MA MA27602A patent/MA27071A1/fr unknown
- 2004-03-31 EC EC2004005041A patent/ECSP045041A/es unknown
- 2004-03-31 CO CO04030711A patent/CO5580790A2/es not_active Application Discontinuation
-
2005
- 2005-02-08 HK HK05101101A patent/HK1070561A1/xx not_active IP Right Cessation
-
2007
- 2007-07-30 CY CY20071101000T patent/CY1106765T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morris et al. | Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. | |
| Kakkar et al. | Efficacy and safety of low‐molecular‐weight heparin (CY216) in preventing postoperative venous thrombo‐embolism: a co‐operative study | |
| Lindmarker et al. | Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis | |
| WESSLER et al. | Theory and practice of minidose heparin in surgical patients: a status report | |
| Ozier et al. | Pharmacological agents: antifibrinolytics and desmopressin | |
| JP2010013455A (ja) | 体外血液回路における血餅形成を防止するためのオリゴ糖の使用 | |
| Matsuo et al. | Development of argatroban, a direct thrombin inhibitor, and its clinical application | |
| Dager et al. | Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants | |
| UA80399C2 (en) | Use of specific dose of fondaparinux sodium for the treatment of acs | |
| JPH02255624A (ja) | 血小板凝集抑制剤 | |
| White et al. | “Rescue” thrombolysis with intracoronary tissue plasminogen activator for failed intravenous thrombolysis with streptokinase for acute myocardial infarction | |
| McKay et al. | Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non–ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials | |
| Morishita et al. | The intracoronary administration of urokinase following direct PTCA for acute myocardial infarction reduces early restenosis | |
| AU2002351915A1 (en) | Uso of specific dose of fondaparinux sodium for the treatment of ACS | |
| ES2262971T3 (es) | Idraparinux (sanorg 34006) para el tratamiento y profilaxis secundaria de sucesos tromboembolicos venosos en pacientes con trombosis venosa intensa. | |
| JP2005509007A6 (ja) | Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用 | |
| Braga et al. | Confirmation that heparin is an alternative means of promoting early reperfusion | |
| Sherry | Low-dose heparin for the prophylaxis of pulmonary embolism | |
| Van Geloven et al. | Comparison of postoperative coumarin, dextran 40 and subcutaneous heparin in the prevention of postoperative deep vein thrombosis | |
| Urbanyi et al. | Prophylaxis Against Thromboembolism in Vascular Surgery: (A Randomised Clinical Trial) | |
| BR112015022070B1 (pt) | Uso de cangrelor | |
| Grewal | The Latest Anticoagulants | |
| Erdem et al. | Administration of heparin by continuous intravenous infusion in the treatment of deep venous thrombosis | |
| Romualdi et al. | Thromboprophylaxis for hip and knee surgery: critical appraisal of rivaroxaban | |
| Margolin et al. | Postoperative thromboembolic complications |